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Plasmodium falciparummutations associated with antimalarial resistance may be beneficial for parasites under drug pressure,
although they may also cause a fitness cost. We herein present an in vitromodel showing how this combined effect on parasite
growth varies with the drug concentration and suggest a calculated drug-specific cost-benefit index, indicating the possible ad-
vantage for mutated parasites. We specifically studied the D-to-Y change at position 1246 encoded by the pfmdr1 gene (pfmdr1
D1246Y) in relation to amodiaquine resistance. Susceptibilities to amodiaquine, desethylamodiaquine, and chloroquine, as well
as relative fitness, were determined for two modified isogenic P. falciparum clones differing only in the pfmdr1 1246 position.
Data were used to create a new comparative graph of relative growth in relation to the drug concentration and to calculate the
ratio between the benefit of resistance and the fitness cost. Results were related to an in vivo allele selection analysis after amodi-
aquine or artesunate-amodiaquine treatment. pfmdr1 1246Y was associated with decreased susceptibility to amodiaquine and
desethylamodiaquine but at a growth fitness cost of 11%. Mutated parasites grew less in low drug concentrations due to a pre-
dominating fitness cost, but beyond a breakpoint concentration they grewmore due to a predominating benefit of increased re-
sistance. The cost-benefit indexes indicated that pfmdr1 1246Y was most advantageous for amodiaquine-exposed parasites. In
vivo, a first drug selection of mutant parasites followed by a fitness selection of wild-type parasites supported the in vitro data.
This cost-benefit model may predict the risk for selection of drug resistance mutations in different malaria transmission settings.
Artemisinin-based combination therapy (ACT) is recom-mended as first-line therapy against uncomplicated Plasmo-
dium falciparummalaria worldwide (1). The artesunate and amo-
diaquine (AQ) combination (ASAQ), which has proven efficacious
in Africa (2), is one of the essential ACTs. AQ and its slowly elimi-
nated activemetabolite desethylamodiaquine (DEAQ) are 4-amino-
quinolines structurally related to chloroquine (CQ). AQ has been
used previously in monotherapy for uncomplicated P. falciparum
malaria in parts of Africa, where it has remained relatively efficacious
despite the similarities and putative cross-resistance with CQ (3, 4).
Several genetic alterations have been associatedwith tolerance/
resistance to different long-acting ACT partner drugs. Resistance
to CQ, AQ, and DEAQ has been associated with the K76T muta-
tion encoded in the P. falciparum CQ resistance transporter gene
(pfcrt) and with the N86Y mutation encoded in the P. falciparum
multidrug resistance 1 gene (pfmdr1) (5–13). Further, theD1246Y
mutation encoded in pfmdr1 (pfmdr1 D1246Y) has been selected
for after treatment with AQ monotherapy and ASAQ combina-
tion therapy in East Africa (8, 14).
Mutations may also affect parasite fitness, however. Biological
fitness is essentially defined as the ability of an organism to survive
and propagate its genes to the next generation (15). It has been
shown for several organisms that the wild-type genotype is nor-
mally the most viable and that mutations that are advantageous
for surviving environmental challenges are acquired at a fitness
cost (16–19). This may also apply to drug resistance in malaria,
wheremutationsmight be disadvantageous in the absence of drug
pressure. This is supported by an in vitro study where transfected
isogenic parasites with a triple mutation in the pfmdr1 gene pro-
duced fewer viable merozoites (20). Further, lower parasite den-
sities in vivowere associated with T at position 76 encoded by pfcrt
(pfcrt 76T) and Y at position 86 encoded by pfmdr1 (pfmdr1 86Y)
in Guinea Bissau (21), and their prevalences decreased after dis-
continued use of CQ in Malawi (22).
The beneficial effect of resistance and a possible fitness cost
counteract each other. The eventual effect on parasite growth and
a possible selection varies upon different settings of malaria ende-
micity and local drug policies. Mathematical models suggest that
an important factor determining the spread of drug resistance is
the proportion of infected people being treated, i.e., the fraction of
the total parasite population under drug pressure (23). In areas of
low endemicity, such as South-East Asia, where a majority of the
infected individuals are symptomatic and treated, the resulting
high-drug-pressure environment is favorable for the selection and
spread of drug-resistantmutated parasites (24, 25). Conversely, in
area of high endemicity, such as sub-Saharan Africa, a large pro-
portion of malaria-infected individuals are semi-immune and
asymptomatic and thus are not treated with antimalarial drugs. In
the latter areas, mutated parasites with significantly reduced fit-
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ness might be continuously deselected and the spread of drug
resistance hampered (23).
Our objectives were to analyze how this combined cost-benefit
effect on parasite growth varies with the drug concentration and
to suggest a calculated drug-specific cost-benefit index, indicating
the possible advantage formutated parasites. Thismay be useful to
predict the potential risk for selection of drug-resistant mutations
in different malaria transmission settings.
MATERIALS AND METHODS
P. falciparum clones for in vitro analyses. Two P. falciparum clones
differing only in the pfmdr1 1246 position were chosen for this study (26).
They were obtained through genetic modification of the CQ-sensitive
D10 clone from Papua New Guinea, i.e., the transfection control, D10
pfmdr1 SND, representing the wild-type pfmdr1 D1246 clone (D10wt),
and D10 pfmdr1 SNY, with a single modification, representing the mu-
tated pfmdr1 1246Y clone (D10mut). Both clones (reference no. MRA-563
and MRA-564, respectively) were obtained from the Malaria Research
and Reference Reagent Resource Center (MR4). Their respective geno-
types were confirmed with PCR-restriction fragment length polymor-
phism (RFLP) and genomic DNA (gDNA) sequencing.
Drug susceptibility analyses. The effect of the pfmdr1D1246Ymuta-
tion on parasite susceptibility to CQ, AQ, and DEAQ was determined
through an HRP2 enzyme-linked immunosorbent assay (HRP2-ELISA)-
based in vitro assay as previously described (27). In vitro-cultured parasite
clones (D10wt and D10mut) were diluted to initial parasitemias of 0.05%
and aliquoted into microculture 96-well plates predosed with ascending
concentrations of 0 to 404 nMCQ, 0 to 67 nMAQ, or 0 to 156 nMDEAQ.
After incubation at 37°C for 72 h, the samples were freeze-thawed, trans-
ferred, and processed in precoated ELISA plates (Cellabs, Sidney, Austra-
lia) for spectrophotometric analysis (Multiskan EX; Thermo Labsystems,
Helsinki, Finland) of HRP2 produced during parasite growth. The 50%
and 90% inhibitory concentration (IC50 and IC90) values were calculated
using the software program HN-NonLin V1.05 Beta (H. Noedl, 2001)
(http://malaria.farch.net). The IC20 values were calculated by applying a
polynomial trend line on the average HRP values and solving its equation
at y 80%(SigmaPlot 11.0; Systat Software Inc., Chicaco, IL). All cultures
were run in duplicate and independently tested for their drug susceptibil-
ities six times.
Relative growth and fitness analyses. The effect of the pfmdr1
D1246Y mutation on relative parasite growth was determined in a com-
petition experiment between synchronized ring-staged cultures of D10wt
and D10mut clones in vitro. The cultures were initially subcultivated to
0.5% parasitemia. Equal aliquots of each culture were added into a 1:1
mixed culture and run in medium containing drug concentrations corre-
sponding to the approximate IC20 value (CQ, 15 nM; AQ, 10 nM; or
DEAQ, 10 nM) or IC50 (CQ, 30 nM; AQ, 20 nM; DEAQ, 20 nM) for the
two clones. In the IC20-based cultures, drug exposure was removed after 6
days, while in the IC50-based cultures, drug exposure was removed after 4
days, when the parasite densities had decreased to approximately 0.1%.
After drug removal, all cultures were washed thoroughly and then run in
drug-free medium until 6 days after the time of parasite recovery, when
regrowth of remaining parasites was established. The time of recovery was
defined as the day when growing ring-stage trophozoites were first ob-
servedmicroscopically after drug removal. In parallel to the drug-exposed
cultures, control cultures were run in drug-free medium for a total of 12
days, including a subcultivation to 0.5% parasitemia after 6 days. Blood
medium was collected for microscopy and spotted on filter paper (3MM
Whatman) for genotyping every second day. All mixed cultures were run
in duplicate.
DNAwas extracted from the filter papers using a QIAampDNAmini-
kit (Qiagen). Amplification was performed through nested PCR using
previously published first primers (28) and specifically designed nest
primers, i.e., forward (5=-TTTTCAAACCAATCTGGATCTG-3=) (biotin-
ylated) and reverse (5=-CTCTGTTTTTGTCCACCTGATAAG-3=). All
PCRs included 1 Taq polymerase reaction buffer, 3 mM magnesium
chloride, 0.2mMdeoxynucleoside triphosphates (dNTPs), 0.4M(each)
primer, and 0.75UofTaqDNApolymerase (PromegaCorporation,Mad-
ison, WI). All PCR products were visualized in an ethidium-bromide-
stained 2% agarose gel under UV transillumination (GelDoc 2000; Bio-
Rad, Hercules, CA). Allele quantification was performed through gDNA
pyrosequencing as previously described (Pyro Gold reagents and PSQ
96MA and PyroMark MD systems; Biotage AB, Uppsala, Sweden) (29).
Specifically for pfmdr1D1246Y, we used a reverse sequencing primer (5=-
TTGAAAATAAGTTTCTAAGA-3=) and the dNTP dispensary entry
CTACGTCTA. Results were adjusted against a standard curve, derived
from a scale of established mixes of the two alleles, and corrected for the
allele exchange output, i.e., the presence of two pfmdr1 fragments in the
transfected genome (26). All samples were run in triplicate. Thus, all sam-
ples were separately run a total of six times for each time point.
Allele selection analysis in vivo. To explore whether a cost-benefit
effect of pfmdr1 D1246Y might be reflected in the parasite selection dy-
namics after AQ or ASAQ therapy in vivo, we analyzed the allele frequen-
cies in baseline infections compared with those in recurrent and more
specifically recrudescent infections during follow-up in three previously
conducted drug efficacy trials in children 5 years old with uncompli-
cated P. falciparum malaria in East Africa. These include an AQ mono-
therapy study in Kenya in 2003 (n 53) (7) and two ASAQ combination
therapy studies in Zanzibar in 2002-2003 (n 198) and 2005 (n 174)
(14, 30). DNA from blood samples collected on filter papers (3MM;
Whatman, United Kingdom) had previously been extracted (Bloodprep;
Applied Biosystems). pfmsp2 genotyping was performed to distinguish
between recrudescent and reinfecting parasites (31). PCR-RFLP was used
for pfmdr1 D1246Y genotyping (5, 28), and mixed results were excluded
since we did not have information on the separate allele proportions
within such infections.
Data analysis and statistics. In vitro susceptibilities were compared
using Student’s t test (SigmaPlot 11.0; Systat Software Inc., Chicago, IL).
Statistical significance was defined as a P value of 0.05 and controlled
according to the Bonferroni method.
The relative growth rate (g) of the mutant clone in the competition
experiment was calculated from the following equation: log(mutt/wtt)
log(mut0/wt0) [t  log(g)]. “mut” and “wt” represent the proportions of
the mutant and the wild-type alleles initially (t0) and after a defined num-
ber (t) of asexual generations during the course of the experiments. g for
the wild-type clone was defined as 1.0, whereas g for the mutant clone
under drug-free conditions corresponds to the relative fitness (w), and the
fitness cost was calculated as 1 w (20, 32).
For comparison, the relative absorbance (abs) of the mutant clone in the
HRP2-ELISA susceptibility analyses was calculated by normalizing against
thebackgroundabsorbance in the followingequation: g (10^abswellAmut/
10^abs wellHmut)/(10^abs wellAwt/10^abs wellHwt).
Ethical considerations. All clinical trials were performed in accor-
dancewith theDeclaration ofHelsinki (33) and ICHgood clinical practice
(34). Informed consent was obtained from parents/guardians of all en-
rolled participants. Ethical approvals were obtained from the Research
Ethics Committee at Karolinska Institutet in Stockholm, Sweden (KI Dnr
03-545, KI Dnr 03-753, and KI Dnr 2005/57-31), the Ethical Research
Committee, Nyanza Province, Kenya (GN.153, vol. 1/50), and the Zanzi-
bar Health Research Council (ZHRC/GC/2002 and ZMRC/RA/2005).
RESULTS
pfmdr1 1246Y is associated with decreased susceptibilities to
AQ/DEAQ. In the drug susceptibility analyses, the profiles dif-
fered for the three drugs (see Table S1 in the supplemental mate-
rial). For CQ, no difference in the IC50 was found between the
D10wt and D10mut clones, whereas for AQ and DEAQ, signifi-
cantly higher IC50s (P 0.001) were found for D10
mut (28.7 nM;
95% confidence interval [CI95], 26.8 to 30.6; and 20.5 nM; CI95,
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19.4 to 21.5 [respectively]) compared with D10wt (15.1 nM; CI95,
13.1 to 17.1; and 15.3 nM; CI95, 13.5 to 17.0 [respectively]).
The cost-benefit effect of pfmdr1 1246Y on parasite growth
varies with the drug concentration. In the competition experi-
ments, parasites exposed to IC20 drug concentrations grew 10 to
15% less than non-drug-exposed parasites and recovered without
delay upondrug removal. Parasites exposed to IC50s ofCQ,AQ, or
DEAQ grew 70 to 80% less than non-drug-exposed parasites and
did not recover until day 6, 14, or 18 after drug removal, respec-
tively.
The fact that the cultures did not grow exactly 20% and 50%
less might be a result of an unequal effect of the approximate IC20
or IC50 on the D10
wt and D10mut clones included in these mixed
cultures.
The relative growth of the D10mut clone differed depending on
the degree of drug exposure (Fig. 1; see also Table S2 in the sup-
plementalmaterial). In the drug-free control cultures, the propor-
tion ofD10mut continuously decreased, from 48.0% to 30.9%over
the full culture period of 12 days (P 0.001), which corresponds
to a negative relative fitness compared with findings for D10wt
(w 0.89). In the cultures exposed to IC20 values of CQ, AQ, or
DEAQ, the proportions of D10mut also decreased, but to a lesser
extent, i.e., from 47.3% to 39.3%, 39.5%, or 39.2%, respectively.
This also corresponds to negative relative growth rates (g  0.95
0.95, or 0.94, respectively). In contrast, in the cultures exposed to
IC50 concentrations of CQ, AQ, or DEAQ, the proportion of
D10mut increased, i.e., from 48.8% to 64.2%, 65.0%, or 56.3%,
respectively. This instead corresponds to positive relative growth
rates (g  1.11, 1.12, or 1.05, respectively). The observation that
D10mut also increased under CQ exposure might be due to the
similar IC50s between the clones, and under such circumstances,
minimal differences in synchronization may interfere.
Model to assess cost-benefit effect of pfmdr1 1246Y. The rel-
ative growth rate of D10mut was thus negative in the drug-free and
IC20-exposed cultures and positive for the IC50-exposed cultures.
To analyze how the relative growth for D10mut versus that for
D10wt varies with the drug concentration, we developed a new
comparative cost-benefit graph (Fig. 2). Under drug-free condi-
tions, the maximum growth rate for D10wt was defined as 100%
(g 1.0), and for D10mut, it was defined as 89%, corresponding to
the relative fitness (w  0.89) derived from the competition ex-
periment. For each clone, the 80%, 50%, and 10% relative growth
rates were then plotted against the respective IC20, IC50, and IC90
values derived from the susceptibility analyses.
Applied trend lines showed that D10mut grew least compared
with D10wt under drug-free conditions. With increasing drug
concentrations, the difference in the growth rate continuously de-
creased until the trend lines potentially crossed at a breakpoint
concentration, after which D10mut grew continuously more.
Hence, the relative growth rates of D10mut parasites were thus
negative in drug concentrations lower than the breakpoint con-
centration, where the benefit of resistance equals the fitness cost,
while in higher concentration the relative growth rates were pos-
itive. The areas between the trend lines correspond to the fitness
cost (area A) and the benefit of resistance (area B) over the full
drug concentration range. The ratio between area B and area A
divided by the breakpoint concentration represents a cost-benefit
index. This index might correspond to the overall advantage of
FIG 1 Proportion (%) (CI95) of the pfmdr1 1246Y allele in the non-drug-
exposed control culture and cultures exposed to an approximate IC20 (6 days)
or IC50 (4 days) of CQ, AQ, or DEAQ. The dashed line is the average original
proportion of the pfmdr1 1246Y allele.
FIG 2 Relative growth rates (%) of D10mut versus D10wt at different concen-
trations of CQ, AQ, and DEAQ (nM). The maximum growth rate for D10mut
without drug exposure was based on the relative fitness (w 0.89). The other
plots are based on the IC20, IC50, and IC90 values. The trend line intercept
indicates the breakpoint where the drug resistance benefit equals the fitness
cost of pfmdr1 1246Y. Area A represents the fitness cost, and area B represents
the drug resistance benefit of pfmdr1 1246Y over the full concentration range.
Cost-Beneﬁt Effect of P. falciparum Mutation
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pfmdr1 1246Y in relation to the breakpoint concentration and as
such its selection potential.
For CQ, the two trend lines never crossed, while the trend lines
crossed at breakpoint concentrations of approximately 5 nM for
AQ and 14 nM for DEAQ. By normalizing the values for relative
growth and drug concentration against those for the D10wt clone
and using the trend line equations, we could geometrically calcu-
late the cost-benefit indexes to zero (no area B) for CQ, 37.9 for
AQ, and 12.0 for DEAQ.
The results were confirmed experimentally by comparing the
relative parasite growth rates with the relative absorbencies de-
rived from the HRP2-ELISA susceptibility analyses, where we
found a similar pattern (data not shown).
The cost-benefit effect influences the selection of the pfmdr1
D1246Y alleles after AQ/DEAQ exposure in vivo. The treatment
outcomes of the AQ and two ASAQ efficacy studies have been
described elsewhere (see Table S3 in the supplemental material)
(7, 14, 30). In summary, the crude treatment failure rates were
36%, 40%, and 29%, while the PCR-adjusted treatment failure
rates were 19%, 8%, and 9%, respectively. No significant differ-
ences in crude or PCR-adjusted treatment failure rates were found
between the two ASAQ studies. Aggregate analysis of the pfmdr1
D1246Y allele frequencies over time in all recurrent parasitemias
during follow-up after ASAQ therapy showed two selection peaks,
i.e., pfmdr1 1246Y on days 8 to 14 and pfmdr1D1246 on days 22 to
28 (Fig. 3). This was followed by a return to the baseline frequen-
cies between days 29 and 42. A similar patternwas also observed in
recrudescent infections specifically, although the number of infec-
tions was small, and after AQ monotherapy, even though the fol-
low-up duration was only 21 days in this study.
The prevalence of children with recurrent parasitemia during
the first selection peak of pfmdr1 1246Y was statistically signifi-
cantly lower after ASAQ combination therapy (7/294; 2%) than
with AQ monotherapy (12/28; 43%) (P 0,001) (Fig. 3; see also
Table S3 in the supplemental material).
DISCUSSION
AQ is an essential ACT partner drug, since ASAQ is presently a
first-line treatment of uncomplicated P. falciparum malaria in
more than 20 African countries (35), although resistance against
AQ/DEAQ both in vitro and in vivo has been described (6–8, 10,
11, 13, 14). The sustained efficacy of AQ as a long-acting partner
drug in ACT is therefore a matter of concern. Understanding the
pharmacodynamic basis of selecting resistance to this quinoline is
thus fundamental. Our in vitro results with allele-exchanged par-
asites confirm that pfmdr1 1246Y is associated with decreased sus-
ceptibility to AQ and DEAQ. This was further supported by its
selection upon drug pressure in the competition experiments.
These results, together with our previous findings of its selection
after AQ/ASAQ treatment in vivo (7, 14), therefore support
pfmdr1 1246Y as a molecular marker associated with resistance to
AQ/DEAQ.
In the competition experiments, the fitness cost for parasites
carrying the pfmdr1 1246Y mutation was determined to 11% per
asexual generation. This cost-benefit effect of the pfmdr1D1246Y
mutation on protein function is supported by results from a re-
cent bioinformatic analysis (36). PfMDR1 is located in the mem-
brane of the digestive vacuole with its nucleotide binding site fac-
ing the parasite cytoplasm (37). Subcellular studies of the
distribution of fluorescein derivatives (Fluo-4) (38) suggest that
PfMDR1 is an importer of diverse substrates into this organelle.
The localization of pfmdr1 D1246Y in the structure of the trans-
porter suggests a functional impact on the influx capacity of the
mutated protein (36). This might decrease the import of amino-
quinoline compounds and hence their access to their active site
inside the digestive vacuole, thus reducing drug susceptibilities
(38). However, the effect might vary due to differences in the
chemical structure and binding sites, which might interact un-
equally with an altered protein structure and function. A reduced
capacity may also affect the import of essential substrates. This
might affect fundamental processes inside the food vacuole. Con-
sequently, parasites carrying the pfmdr1D1246Ymutationmay be
less competitive than wild-type parasites in the absence of amino-
quinoline drug pressure.
We have herein described a new cost-benefit graph, where the
relative growth of parasites with a particular mutation corre-
sponds to a concentration-dependent balance between the spe-
cific benefit of resistance and the fitness cost. Mutated parasites
grow less in low drug concentrations due to a predominating fit-
ness cost, but beyond a breakpoint concentration they potentially
growmore due to a predominating benefit of increased resistance.
Based on the D10mut-versus-D10wt data, we calculated the cost-
FIG 3 Frequencies (%) of the pfmdr1 D1246Y alleles (first axis) in the pro-
portion (%) of children (second axis) with recurrent infections during fol-
low-up (days) after AQ monotherapy in Kenya 2003 (n  53), as well as
recurrent and recrudescent infections after ASAQ combination therapy in
Zanzibar, 2002-2003 and 2005 (n 372).
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benefit indexes representing the drug-specific advantage of
pfmdr1 1246Y in relation to the breakpoint concentrations, which
indicate the risk for selection. Pfmdr1 1246Y was most advanta-
geous for parasites exposed to AQ and second most for parasites
exposed toDEAQ. For parasites exposed to CQ, no similar advan-
tageous effect of this mutation could be observed. Such cost-ben-
efit indexes may potentially be used as a tool to compare the risk
for selection of different mutations associated with tolerance/re-
sistance to different ACT partner drugs.
The in vitrofindingswere consistentwith our findings from the
clinical trials (Fig. 3). AQ is rapidly and extensivelymetabolized by
the hepatic enzyme system CYP2C8 to DEAQ, with the peak con-
centration in plasma within 4 to 6 h and a half-life in plasma of 10
to 14 days (39). Due to the longer half-life, it is probable that
DEAQ is mainly responsible for the antimalarial activity. AQ/
DEAQ, as well as CQ, has large volumes of distribution, and con-
centrations in blood have been shown to vary significantly (7). A
pharmacokinetic study of ASAQ in vivo, however, registered av-
eragemaximumDEAQconcentrations of 350 to 400 ng/ml on day
3 and 40 to 50 ng/ml on day 14 after treatment (40). This suggests
that the registered selection of pfmdr1 1246Y during the first 14
days after AQ/ASAQ treatment is associatedwith a higher concen-
tration of DEAQ, defining the drug selection phase (correspond-
ing to area B in vitro). The selection of pfmdr1 D1246 during the
following 14 days suggests an association with lower concentra-
tions of the drug, defining the fitness selection phase (correspond-
ing to area A in vitro). This phase extends beyond the follow-up
under drug-free conditions. The breakpoint concentration in vitro
would thus correspond to the intercept between the two selection
phases in vivo.
Mutations associated with drug resistance might be supported
by compensatory and/or synergistic mutations (14, 41). In our
cost-benefit graph, this will hypothetically result in a decreased
fitness cost (area A) and/or increased resistance benefit (area B),
alongwith a leftwardmotion of the breakpoint concentration, i.e.,
toward a lower concentration, as well as an increased cost-benefit
index in vitro (Fig. 4). An equivalent rightward motion of the
selection intercept is expected to happen in vivo, as well as an
increased drug selection phase (Fig. 5). However, if synergistic
mutations are associatedwith a further fitness cost, the breakpoint
concentration in vitro and selection intercept in vivo might be
unaffected, and they may not be more selected for.
The frequency of recurrent parasitemias during the critical
drug selection phase was significantly lower after ASAQ than with
AQ monotherapy (Fig. 3; see also Table S3 in the supplemental
material). Thismay suggest that the addition of artesunate reduces
the risk of a pfmdr1 1246Y selection, which eventually may result
in an overall selection of the wild-type allele in the population.
These results may explain our findings from a recent study in
Zanzibar in 2010, where the frequency of pfmdr1 1246Y in base-
line infections actually had decreased despite 7 years’ use of ASAQ
as a first-line treatment (42).
In summary, the results indicate that pfmdr1 1246Y is associ-
atedwith decreased susceptibility toAQ/DEAQbut at a significant
fitness cost to the parasite. Pfmdr1 1246Y is clearly selected for
after AQ/ASAQ therapy during the drug selection phase, while
artesunate seems to decrease such selection through the effective
reduction of early recurrent parasitemias. In addition, pfmdr1
1246Y appears to incur a too-substantial fitness cost to the parasite
to be sustained in competition with wild-type parasites in the ab-
sence of treatment (drug pressure) (23). This may prevent a selec-
tion of pfmdr1 1246Y in the parasite population and development
of resistance, possibly supporting AQ as a valuable and potentially
sustainable partner drug option for ACT in East Africa.
Finally, the describedmodelmay be useful to evaluate the cost-
benefit effects of other mutations associated with resistance to
ACT partner drugs to predict their potential risk for selection in
different malaria transmission settings. Such prediction is impor-
tant for future optimized use of partner drugs and as such the
conditions for sustained ACT efficacy.
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